Valion Bio, Inc. — Form SCHEDULE 13D/A
Filed August 14, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▼ Likely negative
significance 78/100
What the filing says
On August 12–13, 2026, 3i, LP sold 11,676,430 common shares at $0.3969/share (proceeds ~$4.63M) and converted 11,369,441 Series B and C preferred shares into common stock at $0.39/share. Tumim Stone sold 49,242 shares at $1.1060/share (~$54.5K). These transactions occurred within 60 days and represent significant equity restructuring by a major holder in a $4.0M market-cap company.
Why this rating
3i's $4.63M equity sale and massive preferred conversion (11.4M shares) represent ~116% of company market cap—massive dilution and potential loss of confidence signal from insider.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.